Plenty of room for a game changer
in the HCV market, despite latest breakthrough drugs
such as Sovaldi:
"Some private insurers and Medicaid programs are restricting Sovaldi to the sickest patients, at least for now; they're hoping that new competitors, set for approval later this year, will help spur some price competition. That strategy may work, but then again, other hep C drug developers have suggested that they're not interested in a pricing war. All of them, of course, want to profit off their own R&D efforts.
But some payers intend to play hardball. Top PBMExpress Scripts has said that it will compare the various drugs in the new crop of hep C treatments--and will exclude products if they're not considered to be worth their prices."
http://www.fiercepharma.com/story/top-payer-group-shoots-down-gileads-hep-c-drug-sovaldi-price/2014-05-21
- Forums
- ASX - By Stock
- BLT
- hcv drug pricing
hcv drug pricing
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)